"The U.S. Food and Drug Administration yesterday approved Rixubis [Coagulation Factor IX (Recombinant)] for use in people with hemophilia B who are 16 years of age and older. Rixubis is indicated for the control and prevention of bleeding episodes"...
- Patient Information:
Details with Side Effects
BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS, OR FOR PATIENTS WITH WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS.
- For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia.
- For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias.
The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern, and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases and if dose adjustment of the diuretic is ineffective or unwarranted supplementation with potassium salts may be indicated.
DOSAGE AND ADMINISTRATION
The usual dietary potassium intake by the average adult is 50 to 100 mEq per day. Potassium depletion sufficient to cause hypokalemia usually requires the loss of 200 or more mEq of potassium from the total body store.
Dosage must be adjusted to the individual needs of each patient. The dose for the prevention of hypokalemia is typically in the range of 20 mEq per day. Doses of 40-100 mEq per day or more are used for the treatment of potassium depletion. Dosage should be divided if more than 20 mEq per day is given such that no more than 20 mEq is given in a single dose.
K-TAB tablets provide 10 mEq of potassium chloride.
K-TAB (potassium chloride extended-release tablets) tablets should be taken with meals and with a glass of water or other liquid. This product should not be taken on an empty stomach because of its potential for gastric irritation (see WARNINGS).
NOTE: K-TAB (potassium chloride extended-release tablets) tablets are to be swallowed whole without crushing, chewing or sucking the tablets.
K-TAB (potassium chloride extended-release tablets, USP) contains 750 mg of potassium chloride (equivalent to 10 mEq). K-TAB (potassium chloride extended-release tablets) tablets are provided as yellow, ovaloid, extended-release Filmtab® tablets in bottles of 100 (NDC 0074-7804-13),1000 (NDC 0074-7804-19) and 5000 (NDC 0074-7804-59) and in ABBO-PAC® unit dose packages of 100 (NDC 0074-7804-11).
Recommended storage: Store below 86°F (30°C).
Revised: Feb 2008. Manufactured by: Abbott Pharmaceuticals PR Ltd. Barceloneta, PR 00617. Manufactured For: Abbott Laboratories, North Chicago, IL 60064.
Last reviewed on RxList: 7/28/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional K-Tab Information
K-Tab - User Reviews
K-Tab User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.